56 completed, 4 unknown, 2 terminated. 28 Phase 3, 14 Phase 2, 7 Phase 1, 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 27, Terminated 1 |
| Phase 2 | 14 | Completed 13, Terminated 1 |
| Phase 1 | 7 | Completed 7 |
| Phase 4 | 6 | Completed 4, Unknown 2 |
Follow dasabuvir: new trials by email Literature Review of dasabuvir trials Research Report on dasabuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 | |
| Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B VEKIRAX, EXVIERA - HCV Coinfection | Phase 4 | Completed | HaEmek Medical Center, Israel | 7 | 2017-06-22 | 2019-08-09 |
| Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks - Hepatitis C Infection | Completed | Hepa C | 200 | 2017-02-20 | 2018-05-21 | |
| Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection. Ombitasvir-Paritaprevir-Ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis, C Virus | Phase 4 | Unknown | University of Modena and Reggio Emilia | 75 | 2016-12-01 | 2016-11-01 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 256 | 2016-07-07 | 2019-10-11 | |
| Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Hepatitis C, Acute | Phase 3 | Completed | Kirby Institute | 83 | 2016-06-01 | 2022-08-22 |
| Study of Oral Treatments for Hepatitis C SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir) - Chronic Hepatitis C | Phase 4 | Completed | University of Florida | 1275 | 2016-06-01 | 2021-12-06 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 216 | 2016-04-05 | 2019-03-15 | |
| A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults ombitasvir/paritaprevir/ritonavir, dasabuvir - Hepatitis C Infection, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 166 | 2015-11-24 | 2021-07-30 |
| The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 101 | 2015-11-05 | 2019-05-06 | |
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | AbbVie | 64 | 2015-10-28 | 2021-10-05 |
| Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 105 | 2015-10-28 | 2019-12-10 |
| Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 565 | 2015-10-13 | 2019-03-27 | |
| Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C, Genotype 1 or 4 | Completed | AbbVie | 314 | 2015-10-07 | 2019-05-06 | |
| Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 18 | 2015-09-30 | 2017-12-04 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV) - HIV Infections, Hepatitis C | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2015-09-16 | 2021-11-04 |
| Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects ABT-450/r/ABT-267, ABT-333 - Healthy Volunteer | Phase 1 | Completed | AbbVie | 18 | 2015-09-01 | 2015-10-19 |
| ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis ABT-450/r/ABT-267, ABT-333, ribavirin - Chronic Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 104 | 2015-07-20 | 2018-10-09 |
| Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment Paritaprevir, Ritonavir, Dasabuvir - Hepatitis C Virus | Phase 4 | Unknown | Nova Scotia Health Authority | 44 | 2015-07-10 | 2024-08-23 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin - Chronic Hepatitis C Infection | Phase 3 | Terminated | AbbVie | 3 | 2015-07-01 | 2017-12-12 |
Showing 20 of 62. Sign in to see all of them.
Hepatitis C (45) · Hepatitis C, Chronic (36) · Fibrosis (7) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Hepatitis, Chronic (2) · Kidney Diseases (2) · Infections (1) · Kidney Failure, Chronic (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
AbbVie (34) · AbbVie (prior sponsor, Abbott) (12) · Abbott (4) · Valme University Hospital (2) · HaEmek Medical Center, Israel (1) · Hepa C (1) · Kaiser Permanente (1) · Kirby Institute (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nova Scotia Health Authority (1) · Ottawa Hospital Research Institute (1) · Qing XIe (1) · University of Florida (1) · University of Modena and Reggio Emilia (1)
United States (14) · Puerto Rico (6) · Spain (6) · United Kingdom (4) · Australia (3) · Canada (3) · Germany (3) · Israel (3) · Belgium (2) · China (2) · France (2) · Italy (2) · New Zealand (2) · Algeria (1) · Austria (1)
Daniel Cohen, MD (5) · Eric Cohen, MD (4) · Dan Cohen, MD (3) · Emily Dumas, PhD (3) · Yan Luo, MD (3) · Roger Trinh, MD (2) · Andrew L Campbell, MD (1) · Daniel Cohen (1) · Daniel E Cohen, MD (1) · David R Nelson, MD (1) · Gail Matthews, MBBS PhD (1)
PMID 29377566, PMID 30739368, PMID 29909549, PMID 26321288, PMID 30291369, PMID 30853642, PMID 37671831, PMID 23281975, PMID 24428468, PMID 24720679, PMID 24720703, PMID 24818763, PMID 25386767, PMID 25451053, PMID 25839406, PMID 26100711, PMID 26248955, PMID 26596948, PMID 26597291, PMID 26711747, PMID 26743093, PMID 26976799, PMID 27115431, PMID 27415157, PMID 27762283, PMID 27882706, PMID 27919899, PMID 28004322, PMID 28137633, PMID 28412293, PMID 28599618, PMID 29377515, PMID 30160363, PMID 30980576, PMID 32406487, PMID 32451952, PMID 34255381, PMID 34312544, PMID 35182741, PMID 35657133, PMID 36972796, PMID 37771545
2014 (6), 2015 (4)